Anti-Estrogen Receptor Beta2 [57/3]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-Estrogen Receptor Beta2 [57/3]
• Alternate name: Estrogen receptor beta, ER-beta, Nuclear receptor subfamily 3 group A member 2
• Cancer: Breast cancer;Gynaecologic cancer
• Cancers detailed: Breast cancer;Broadly Applicable;Ovarian
• Research fields: Cancer;Immunology
• Clone: 57/3
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Molecular weight: 53 kDa
• Strain: Balb/c
• Reactivity: Human
• Host: Mouse
• Application: IHC ; IF ; WB
• Description: Estrogen receptors are commonly over-expressed in cancers. Clone 57/3 recognizes Estrogen Receptor Beta (ERÎ?) 2 and is useful in determining the expression of ERÎ?2 in cancer cells via various analysis methods.
• Immunogen: Recognizes ER?2 isomer at sequence CGMKMETLLPEATMEQ
• Isotype: IgG1
• Myeloma used: Sp2/0-Ag14
• Recommended controls: Ovary

Target Details

• Target: Estrogen Receptor ? 2
• Molecular weight: 53 kDa
• Tissue cell line specificity: Ovary
• Target background: Estrogen receptors are commonly over-expressed in cancers. Clone 57/3 recognizes Estrogen Receptor Beta (ER?) 2 and is useful in determining the expression of ER?2 in cancer cells via various analysis methods.

Applications

• Application: IHC ; IF ; WB

Handling

• Format: Liquid
• Unit size: 100 ug
• Shipping conditions: Dry ice

References

• Buttarelli et al. 2017. Gynecol Oncol. 145(2):352-360. PMID: 28228232.
• Hormone receptor expression profile of low-grade serous ovarian cancers.
• Zannoni et al. 2016. Histopathology. 68(4):541-8. PMID: 26132417.
• Sexual dimorphism in medulloblastoma features.
• Gender effect in experimental models of human medulloblastoma: does the estrogen receptor ? signaling play a role?
• Ciucci et al. 2014. PLoS One. 9(7):e101623. PMID: 25000562.
• Collins et al. 2009. BMC Cancer. 9:330. PMID: 19758455.
• Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
• Carpino et al. 2007. Eur J Endocrinol. 157(2):239-44. PMID: 17656605.
• Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
• Skliris et al. 2006. Br J Cancer. 95(5):616-26. PMID: 16880783.
• Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.
• Wong et al. 2005. J Pathol. 207(1):53-60. PMID: 15954165.
• ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
• Sierens et al. 2004. J Mol Endocrinol. 32(3):703-18. PMID: 15171710.
• Cloning of oestrogen receptor beta from Old and New World primates: identification of splice variants and Fn analysis.
• Critchley et al. 2002. J Clin Endocrinol Metab. 87(11):5265-73. PMID: 12414901.
• Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
• Ogawa et al. 1998. Nucleic Acids Res. 26(15):3505-12. PMID: 9671811.
• Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human.